Tetra Bio-Pharma Announces FDA Clearance on IND, allowing U.S. Reborn1(TM) Clinical Trial to Commence

January 29, 2021 6:30 AM

OTTAWA, ON / ACCESSWIRE / January 29, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP) (OTCQB:TBPMF), a leader in cannabinoid-derived drug discovery and development announced today that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application, allowing Tetra to initiate its QIXLEEFTM Reborn1TM clinical trial in cancer patients with breakthrough...

Read more

Helix Biopharma Corp. Reports Voting Results

January 28, 2021 5:40 PM

RICHMOND HILL, ON / ACCESSWIRE / January 28, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47, today announced the voting results of the Company's annual and special meeting of shareholders held on January 28, 2021 (the "Meeting"). In...

Read more

MJTV Joint Venture Partner Genesis Botanical Signs Contract for 40 Acres of Hemp Biomass for Its CBD Extraction Facility as Well as Further Expansion

January 27, 2021 5:45 PM

CHEYENNE, WY / ACCESSWIRE / January 27, 2021 / MJ Biotech, Inc. (MJTV), is pleased to announce, its wholly-owned Subsidiary, New England Biotech's partner Genesis Botanical, signed its first contract with a Maine farmer to provide 40 acres of hemp biomass for extraction for the 2021 farming season. Company executives met with the farmer and his team at their indoor facility to discuss and advise on the different varieties of hemp to be...

Read more

Viewpoint Molecular Targeting(TM) to Present at the 2021 SNMMI Mid-Winter Meeting

January 27, 2021 10:00 AM

CORALVILLE, IA / ACCESSWIRE / January 27, 2021 / Viewpoint Molecular Targeting, Inc. ("Viewpoint" or the "Company"), a radiopharmaceutical company developing precision α-particle oncology therapeutics and complementary diagnostic imaging agents, today announced its abstract has been selected for oral presentation at the 2021 SNMMI Mid-Winter Meeting, being held virtually January 28-31, 2021. Summarized below is the...

Read more

Financier Sheldon Inwentash Joins Wuhan General Group as Strategic Advisor

January 27, 2021 9:00 AM

CAPE TOWN, SA / ACCESSWIRE / January 27, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to announce today that the Company has entered into an advisory agreement with Sheldon Inwentash. Sheldon is well-known in the North American capital markets for his investment prowess...

Read more

EV Biologics Has Engaged Foley & Lardner LLP for Legal Counsel in Intellectual Property

January 26, 2021 8:15 AM

CHEYENNE, WY / ACCESSWIRE / January 26, 2021 / EV Biologics Corp, OTC: YECO today announced that it has entered into an engagement agreement with the esteemed international law firm, Foley & Lardner LLP, est. 1842. The firm is at the top of Intellectual Property Law in Biotechnology and Organics and has a specialty in stem cell and extracellular vesicle technology. EV Biologics CEO, Daniel Mckinney said "with Foley & Lardner, we...

Read more

Edesa Biotech to Study Its Investigational Drug as Potential Rescue Therapy

January 26, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / January 26, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, has received regulatory approval from the U.S. Food and Drug Administration (FDA) and Health Canada to add a sub-study to its ongoing Phase 2/Phase 3 clinical study of its investigational drug, EB05, for the treatment of Acute Respiratory Distress Syndrome (ARDS) - the leading cause of death in COVID-19 patients. The...

Read more

Applied UV Receives Notification of Patent Allowance from European Patent Office for Pathogen Destroying Devices

January 25, 2021 12:30 PM

Adds to Company's Patent Protecting Disinfection Technology Portfolio Addressing Global Challenge of HAI's and Pathogen Spread in Public Spaces MOUNT VERNON, NY / ACCESSWIRE / January 25, 2021 / Applied UV, Inc. (NasdaqCM:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") to destroy pathogens safely, thoroughly,...

Read more

Exceltox Laboratories, LLC RECEIVES ACCREDITATION FROM COLLEGE OF AMERICAN PATHOLOGISTS

January 22, 2021 3:30 PM

IRVINE, CA / ACCESSWIRE / January 22, 2021 / The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to Exceltox Laboratories, Irvine, based on results of a recent on-site inspection as part of the CAP's Accreditation Programs. Exceltox Laboratories is a CLIA-certified laboratory offering advanced clinical and toxicology testing services. Located in Irvine, California, currently they offer...

Read more

Integrated BioPharma Announces Upgrade to OTCQX

January 22, 2021 9:00 AM

HILLSIDE, NJ / ACCESSWIRE / January 22, 2021 / Integrated BioPharma, Inc. (OTCQX:INBP) (the "Company" or "INBP"), upgraded to the OTCQX® Best Market from OTCQB® Venture Market as of today. OTC Markets Group Inc. (OTCQX:OTCM) is an operator of financial markets for 11,000 U.S. and global securities. Integrated BioPharma, Inc. begins trading today on OTCQX under the symbol "INBP." U.S. investors can find...

Read more

Havn Life Sciences Announces Inclusion in First Psychedelic Exchange Traded Fund

January 22, 2021 8:00 AM

VANCOUVER, BC / ACCESSWIRE / January 22, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is pleased to announce that it will be included in the First Psychedelics Exchange Traded Fund ("ETF"). The ETF will begin traded on the Neo...

Read more

MJ Biotech, Inc. (MJTV), Subsidiary, Joint Venture Partner Genesis Botanical Research, Begins Construction of CBD Extraction Facility

January 21, 2021 7:00 AM

CHEYENNE, WY / ACCESSWIRE / January 21, 2021 / MJ Biotech Inc. (MJTV) is pleased to announce that it's subsidiary New England Biotech's partner Genesis Botanical, has begun construction of the CBD Extraction facility after securing a location. The facility will be owned by MJTV's wholly owned subsidiary, New England Biotech. The site of the facility in Sagadahoc County, in Mid-Coast Central Maine on agricultural land and...

Read more

Edesa Biotech to Join Panel Discussion at Government COVID-19 Event

January 20, 2021 7:45 AM

TORONTO, ON / ACCESSWIRE / January 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by Clinical Trials Ontario in collaboration with the Bureau du Québec à Toronto and the Canadian and International Innovation Partnerships Directorate. As part of a government and industry...

Read more

Enzolytics, Inc. Receives Official Filing Receipt for Multiple Sclerosis Patent Application

January 19, 2021 9:30 AM

Third Tranche of $1.2 Million Financing Completed COLLEGE STATION, TX / ACCESSWIRE / January 19, 2021 / Enzolytics, Inc. (OTC PINK:ENZC)(the "Company") today, announced it has received the official filing receipt from the U.S. Patent Office confirming the filing of its patent application for "Nuclear Proteins Isolated from Mammalian Spinal Cord Immune Factor - Pharmaceutical Composition for Treatment" and has received the...

Read more

Viewpoint Molecular Targeting(TM) Awarded $5 Million in Phase II SBIR Grants from the National Institutes of Health - National Cancer Institute

January 19, 2021 9:00 AM

- $2 million Phase II SBIR grant awarded to advance image-guided alpha-particle therapy for metastatic melanoma and radioisotope production technologies - Second year of a $2 million Phase II SBIR funding to begin a Phase 1 clinical imaging trial of complementary Pb-203 and Ga-68 diagnostics for metastatic melanoma - $2 million Phase II Small Business Innovation Research (SBIR) grant awarded to fund development activities and advance...

Read more

FDA Lifts Partial Clinical Hold on PRS-343 Phase 1 Studies

January 19, 2021 8:00 AM

BOSTON, MA / ACCESSWIRE / January 19, 2021 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration (FDA) has lifted the previously announced partial clinical hold on the phase 1 studies of PRS-343. As...

Read more

Nascent Biotech Research Partner, Manhattan BioSolutions, to Present at the ACCESS CHINA Forum at the 2021 JPMorgan Healthcare Conference

January 19, 2021 8:00 AM

SAN DIEGO, CA / ACCESSWIRE / January 19, 2021 / Nascent Biotech, Inc. (OTCQB:NBIO). Nascent Biotech Research Partner, Manhattan BioSolutions (MABS), Inc. announced that it will be presenting at the "ACCESS CHINA Forum at JP Morgan Week 2021" which is being held online on January 4th to 30th, 2021. Dr. Boris Shor, Co-founder and CEO of MABS, will be hosting presentation on Wednesday, January 20, 2021 at 9:20PM, EST. Sean Carrick,...

Read more

Mosaic ImmunoEngineering Inc. Announces Upgrade to OTCQB Venture Market and Upcoming Presentation at the B. Riley Oncology Investor Conference

January 19, 2021 8:00 AM

NOVATO, CA / ACCESSWIRE / January 19, 2021 / Mosaic ImmunoEngineering Inc., (the "Company" or "Mosaic") (OTC PINK:CPMV), a development-stage biotechnology company focused on bridging immunology and engineering to develop novel immunotherapies to treat and prevent cancer and infectious diseases, announced today that it will begin trading on the OTCQB® Venture Market as of today, January 19, 2021. The Company also announced...

Read more

MJ Biotech Wholly Owned Subsidiary, New England Biotech And Joint Venture Partner Genesis Botanical Research Secures CBD Extraction Facility Location

January 19, 2021 8:00 AM

CHEYENNE, WY / ACCESSWIRE / January 19, 2021 / MJ Biotech, Inc. (OTC PINK:MJTV), is pleased to announce that it's partner Genesis Botanical Research, has secured the location for the first of their CBD extraction facilities. The facility, once constructed, will be owned by MJTV's wholly owned subsidiary New England Biotech, Inc. This first CBD extraction facility will be located in Sagadahoc County in the Mid-Coast-Central Maine area....

Read more

Havn Life to Support Canadian Counterpart of Veterans' Organization, Heroic Hearts

January 18, 2021 8:00 AM

Havn Life to grow its partnership with the US-based veterans' organization by funding and supporting the launch of its Canadian counterpart. VANCOUVER, BC / ACCESSWIRE / January 18, 2021 / Havn Life Sciences Inc. (CSE:HAVN)(OTC PINK:HAVLF)(FSE:5NP) (the "Company" or "Havn Life") a biotechnology company pursuing standardized extraction of psychoactive compounds and the development of natural healthcare products, is...

Read more